315 related articles for article (PubMed ID: 25749420)
1. Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment.
Yang HZ; Ma Y; Zhou Y; Xu LM; Chen XJ; Ding WB; Zou HB
Cancer Lett; 2015 May; 361(1):128-36. PubMed ID: 25749420
[TBL] [Abstract][Full Text] [Related]
2. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Liu YS; Hsu HC; Tseng KC; Chen HC; Chen SJ
Biomed Pharmacother; 2013 Oct; 67(8):791-9. PubMed ID: 24138824
[TBL] [Abstract][Full Text] [Related]
3. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
Zhang H; Tang J; Li C; Kong J; Wang J; Wu Y; Xu E; Lai M
Cancer Lett; 2015 Jan; 356(2 Pt B):781-90. PubMed ID: 25449431
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
5. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Ayadi M; Bouygues A; Ouaret D; Ferrand N; Chouaib S; Thiery JP; Muchardt C; Sabbah M; Larsen AK
Oncotarget; 2015 Jul; 6(21):18518-33. PubMed ID: 26041882
[TBL] [Abstract][Full Text] [Related]
6. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.
Xue Z; Sun PH; Zhu LM; Jiang SH; Qiao MM; Chi AL; Tu SP
Oncol Rep; 2011 Apr; 25(4):1039-46. PubMed ID: 21279308
[TBL] [Abstract][Full Text] [Related]
8. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
[TBL] [Abstract][Full Text] [Related]
9. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.
Dong TT; Zhou HM; Wang LL; Feng B; Lv B; Zheng MH
Ann Surg Oncol; 2011 Jun; 18(6):1797-804. PubMed ID: 21267784
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity.
Munakata K; Uemura M; Tanaka S; Kawai K; Kitahara T; Miyo M; Kano Y; Nishikawa S; Fukusumi T; Takahashi Y; Hata T; Nishimura J; Takemasa I; Mizushima T; Ikenaga M; Kato T; Murata K; Carethers JM; Yamamoto H; Doki Y; Mori M
Clin Cancer Res; 2016 Nov; 22(21):5277-5286. PubMed ID: 27166395
[TBL] [Abstract][Full Text] [Related]
11. Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells.
Du H; Yang W; Chen L; Shi M; Seewoo V; Wang J; Lin A; Liu Z; Qiu W
Oncol Rep; 2012 Jan; 27(1):143-50. PubMed ID: 21935576
[TBL] [Abstract][Full Text] [Related]
12. SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers.
Suzuki Y; Haraguchi N; Takahashi H; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Ishii H; Doki Y; Mori M; Yamamoto H
Int J Oncol; 2013 Jan; 42(1):161-7. PubMed ID: 23175153
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
15. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Wang X; Zuo D; Chen Y; Li W; Liu R; He Y; Ren L; Zhou L; Deng T; Wang X; Ying G; Ba Y
Br J Cancer; 2014 Nov; 111(10):1965-76. PubMed ID: 25321193
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
Bose D; Zimmerman LJ; Pierobon M; Petricoin E; Tozzi F; Parikh A; Fan F; Dallas N; Xia L; Gaur P; Samuel S; Liebler DC; Ellis LM
Br J Cancer; 2011 Nov; 105(11):1759-67. PubMed ID: 22045189
[TBL] [Abstract][Full Text] [Related]
17. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Pang R; Law WL; Chu AC; Poon JT; Lam CS; Chow AK; Ng L; Cheung LW; Lan XR; Lan HY; Tan VP; Yau TC; Poon RT; Wong BC
Cell Stem Cell; 2010 Jun; 6(6):603-15. PubMed ID: 20569697
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
20. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
